Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV002060249 | SCV000614338 | uncertain significance | not provided | 2021-06-22 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001127721 | SCV001287064 | uncertain significance | Congenital nephrotic syndrome | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Labcorp Genetics |
RCV002060249 | SCV002367775 | likely benign | not provided | 2024-12-16 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001277293 | SCV005654315 | likely benign | Finnish congenital nephrotic syndrome | 2024-02-15 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001277293 | SCV001464215 | uncertain significance | Finnish congenital nephrotic syndrome | 2019-12-05 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003942697 | SCV004771761 | uncertain significance | NPHS1-related disorder | 2024-02-22 | no assertion criteria provided | clinical testing | The NPHS1 c.1619C>A variant is predicted to result in the amino acid substitution p.Ala540Glu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.068% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |